The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.
|Articles|March 16, 2007
- Spring 2007
- Volume 6
- Issue 2
www.komen.org
Author(s)Elizabeth Whittington
Susan G. Komen Breast Cancer Foundation’s new name and look.
Advertisement
To celebrate its 25th year, the Susan G. Komen Breast Cancer Foundation made some changes—most notably its name. Now Susan G. Komen for the Cure, the nonprofit entered 2007 with a new name, a trendy advertising campaign and a revamped website packed with videos, newsletters, message boards, events and more. The group also launched
Articles in this issue
over 19 years ago
Message from the Editorover 19 years ago
Letters from Our Readersover 19 years ago
Surfer Wisdomover 19 years ago
Deadly Accuracyover 19 years ago
The Weight Gain Mysteryover 19 years ago
Hazardous to Your Heartover 19 years ago
What Five Years Really Meansover 19 years ago
Prescription for Troubleover 19 years ago
Liver Cancer: More Cases, More CausesAdvertisement
Related to this article
A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.
The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.
Advertisement
Advertisement
Trending on CURE
1
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
2
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
Anktiva for Papillary Bladder Cancer: What Patients Should Know
5